1. Home
  2. NUVL vs VNT Comparison

NUVL vs VNT Comparison

Compare NUVL & VNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$109.56

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Vontier Corporation

VNT

Vontier Corporation

HOLD

Current Price

$36.07

Market Cap

5.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
VNT
Founded
2017
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
5.1B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
VNT
Price
$109.56
$36.07
Analyst Decision
Strong Buy
Buy
Analyst Count
14
10
Target Price
$134.29
$46.11
AVG Volume (30 Days)
756.3K
1.1M
Earning Date
10-30-2025
10-30-2025
Dividend Yield
N/A
0.28%
EPS Growth
N/A
4.02
EPS
N/A
2.73
Revenue
N/A
$3,043,900,000.00
Revenue This Year
N/A
$2.79
Revenue Next Year
N/A
$3.27
P/E Ratio
N/A
$13.28
Revenue Growth
N/A
1.76
52 Week Low
$55.54
$27.22
52 Week High
$112.88
$43.88

Technical Indicators

Market Signals
Indicator
NUVL
VNT
Relative Strength Index (RSI) 62.75 44.54
Support Level $103.51 $35.26
Resistance Level $112.11 $36.31
Average True Range (ATR) 5.16 0.77
MACD -0.24 0.29
Stochastic Oscillator 83.81 97.33

Price Performance

Historical Comparison
NUVL
VNT

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About VNT Vontier Corporation

Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.

Share on Social Networks: